Understanding and treating systemic histiocytic neoplasms
Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms
['FUNDING_R37'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11063105
This study is looking at rare blood disorders called systemic histiocytic neoplasms to understand how certain genetic changes, like the BRAFV600E mutation, affect them, and it aims to find better treatments using targeted therapies; if you're a patient with this condition, your response to these treatments will be closely monitored to help improve care for everyone.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11063105 on ClinicalTrials.gov |
What this research studies
This research focuses on systemic histiocytic neoplasms, which are rare blood disorders affecting the monocyte/macrophage lineage. It investigates the genetic mutations that drive these conditions, particularly the BRAFV600E mutation, and explores targeted therapies like BRAF and MEK inhibitors. Patients will be monitored for their response to these treatments through blood tests that measure specific biomarkers, providing insights into the effectiveness of the therapies. The goal is to improve treatment outcomes for patients with these complex disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with systemic histiocytic neoplasms, particularly those with BRAFV600E mutations or other related genetic alterations.
Not a fit: Patients with histiocytic neoplasms that do not have identifiable genetic mutations or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with systemic histiocytic neoplasms, potentially improving their quality of life and survival rates.
How similar studies have performed: Previous research has shown success with targeted therapies for BRAFV600E-mutant histiocytic neoplasms, indicating a promising approach for similar conditions.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DIAMOND, ELI LOUS — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: DIAMOND, ELI LOUS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.